Aktuellt
SENASTE
Redeye is encouraged by the first report from Annexin’s imaging study (n=16), which indicates site-specific accumulation of ANXV in vessels affected by RVO in a patient, suggesting that ANXV reaches its target. The study will now continue, including in more patients and higher doses, to further substantiate this. In today’s release, Annexin also mentions that the study has been approved to include patients with diabetic retinopathy, which could give further insights, although is not the target indication for the moment. The trial is expected to be finalized by the end of 2023 and is thus run in tandem with the company’s ongoing phase II trial in RVO patients, where we expect initial data in H1 that could have a more significant impact on our valuation.
LÄS MER
